Anika Therapeutics Inc.

21.74-1.26-5.48%Vol 122.00K1Y Perf -43.11%
Aug 11th, 2022 16:00 DELAYED
BID15.80 ASK34.81
Open23.07 Previous Close23.00
Pre-Market- After-Market21.74
 - -  - -%
Target Price
29.00 
Analyst Rating
Hold 3.00
Potential %
33.39 
Finscreener Ranking
★★★★+     55.98
Insiders Trans % 3/6/12 mo.
100/100/100 
Value Ranking
★★★★     55.80
Insiders Value % 3/6/12 mo.
100/100/100 
Growth Ranking
★★★     52.30
Insiders Shares Cnt. % 3/6/12 mo.
100/100/100 
Income Ranking
 —    -
Price Range Ratio 52W %
6.92 
Earnings Rating
Strong Sell
Market Cap317.38M 
Earnings Date
3rd Aug 2022
Alpha-0.01 Standard Deviation0.13
Beta1.02 

Today's Price Range

21.6323.07

52W Range

19.9545.81

5 Year PE Ratio Range

-19.1059.20

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-4.14%
1 Month
-3.85%
3 Months
-0.46%
6 Months
-28.27%
1 Year
-43.11%
3 Years
-61.33%
5 Years
-57.97%
10 Years
48.29%

TickerPriceChg.Chg.%
ANIK21.74-1.2600-5.48
AAPL168.49-0.7500-0.44
GOOG119.82-0.8300-0.69
MSFT287.02-2.1400-0.74
XOM93.192.62002.89
WFC45.250.92002.08
JNJ167.14-3.5300-2.07
FB196.640.99000.51
GE78.901.76002.28
JPM120.141.75001.48
 
ProfitabilityValueIndustryS&P 500US Markets
55.80
-12.30
-2.70
9.30
-6.78
RevenueValueIndustryS&P 500US Markets
112.05M
7.70
10.38
6.80
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.19-0.1236.84
Q01 2022-0.24-0.1154.17
Q04 2021--0.23-
Q03 20210.080.05-37.50
Q02 20210.040.09125.00
Q01 20210.010.06500.00
Q04 20200.110.129.09
Q03 20200.13-0.45-446.15
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.19-46.15Negative
9/2022 QR-0.15-66.67Negative
12/2022 FY-0.5520.29Positive
12/2023 FY-0.39-34.48Negative
Next Report Date-
Estimated EPS Next Report-0.19
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume122.00K
Shares Outstanding14.60K
Shares Float10.55M
Trades Count2.42K
Dollar Volume2.71M
Avg. Volume91.31K
Avg. Weekly Volume104.21K
Avg. Monthly Volume69.28K
Avg. Quarterly Volume100.45K

Anika Therapeutics Inc. (NASDAQ: ANIK) stock closed at 21.74 per share at the end of the most recent trading day (a -5.48% change compared to the prior day closing price) with a volume of 122.00K shares and market capitalization of 317.38M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 154 people. Anika Therapeutics Inc. CEO is Cheryl R. Blanchard.

The one-year performance of Anika Therapeutics Inc. stock is -43.11%, while year-to-date (YTD) performance is -39.32%. ANIK stock has a five-year performance of -57.97%. Its 52-week range is between 19.9508 and 45.81, which gives ANIK stock a 52-week price range ratio of 6.92%

Anika Therapeutics Inc. currently has a PE ratio of -210.70, a price-to-book (PB) ratio of 1.18, a price-to-sale (PS) ratio of 2.88, a price to cashflow ratio of 37.90, a PEG ratio of 2.32, a ROA of -0.48%, a ROC of -0.54% and a ROE of -0.60%. The company’s profit margin is -6.78%, its EBITDA margin is -2.70%, and its revenue ttm is $112.05 Million , which makes it $7.70 revenue per share.

Of the last four earnings reports from Anika Therapeutics Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.19 for the next earnings report. Anika Therapeutics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Anika Therapeutics Inc. is Hold (3), with a target price of $29, which is +33.39% compared to the current price. The earnings rating for Anika Therapeutics Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Anika Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Anika Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 11.38, ATR14 : 1.01, CCI20 : -133.31, Chaikin Money Flow : -0.23, MACD : 0.07, Money Flow Index : 40.27, ROC : -5.93, RSI : 39.97, STOCH (14,3) : 3.08, STOCH RSI : 0.00, UO : 36.86, Williams %R : -96.92), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Anika Therapeutics Inc. in the last 12-months were: Cheryl R. Blanchard (Buy at a value of $207 143), Cheryl R. Blanchard (Option Excercise at a value of $0), David Colleran (Buy at a value of $72 033), David Colleran (Option Excercise at a value of $0), Jeffery Scott Thompson (Buy at a value of $49 318), Michael L. Levitz (Buy at a value of $129 715), Michael L. Levitz (Option Excercise at a value of $0), Thomas Finnerty (Option Excercise at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
2 (100.00 %)
3 (100.00 %)
3 (100.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingHold
3.00
Hold
3.00
Hold
3.00

Anika Therapeutics Inc.

Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company's product profile includes Orthobiologics, Dermal, Surgical and other of which Orthobiologics products generates maximum revenue to the company.

CEO: Cheryl R. Blanchard

Telephone: +1 781 457-9000

Address: 32 Wiggins Avenue, Bedford 01730, MA, US

Number of employees: 154

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

89%11%

Bearish Bullish

75%25%

Bearish Bullish

70%30%

TipRanks News for ANIK


News

Stocktwits